Romano Brothers & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.68M Sell
46,486
-17,814
-28% -$1.02M 0.27% 92
2026
Q1
$3.9M Buy
64,300
+10
+0% +$583 0.44% 71
2025
Q4
$3.47M Sell
64,290
-5,947
-8% -$286K 0.39% 71
2025
Q3
$3.17M Sell
70,237
-1,970
-3% -$92K 0.36% 80
2025
Q2
$3.34M Sell
72,207
-1,840
-2% -$90.3K 0.41% 68
2025
Q1
$4.52M Sell
74,047
-301
-0.4% -$17.5K 0.58% 53
2024
Q4
$4.21M Sell
74,348
-6,801
-8% -$380K 0.53% 57
2024
Q3
$4.2M Sell
81,149
-915
-1% -$42.9K 0.52% 57
2024
Q2
$3.41M Sell
82,064
-11,338
-12% -$507K 0.47% 62
2024
Q1
$5.07M Sell
93,402
-6,147
-6% -$313K 0.69% 43
2023
Q4
$5.11M Sell
99,549
-12,716
-11% -$667K 0.76% 38
2023
Q3
$6.52M Sell
112,265
-4,247
-4% -$260K 1.01% 20
2023
Q2
$7.45M Sell
116,512
-1,397
-1% -$93.7K 1.11% 16
2023
Q1
$8.15M Sell
117,909
-416
-0.4% -$29.3K 1.26% 14
2022
Q4
$8.51M Sell
118,325
-834
-0.7% -$62.9K 1.29% 13
2022
Q3
$8.47M Buy
+119,159
New +$8.64M 1.37% 13

Other funds holding BMY

Romano Brothers & Co's BMY Position: Q2 2026 in Review

Romano Brothers & Co reduced its Bristol-Myers Squibb (BMY) stake by 28% in Q2 2026, selling an estimated $1.02M and leaving 46,486 shares worth $2.68M. The position accounts for 0.27% of the portfolio, ranked #92.

Romano Brothers & Co first reported a position in BMY in Q3 2022 and has held it in 16 quarters since. The position peaked at $8.51M in Q4 2022. 1,031 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Romano Brothers & Co held 46,486 shares of Bristol-Myers Squibb worth $2.68M as of Q2 2026.
  • Romano Brothers & Co sold 17,814 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.02M.
  • Bristol-Myers Squibb made up 0.27% of Romano Brothers & Co's portfolio in Q2 2026, its #92 holding.
  • Romano Brothers & Co first reported a position in Bristol-Myers Squibb in Q3 2022 and has held it in 16 quarters since.
  • Romano Brothers & Co's Bristol-Myers Squibb position peaked at $8.51M in Q4 2022.
  • 1,031 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Romano Brothers & Co's 13F filing for Q2 2026, filed 22 Jul 2026.